Cancer Biomarker Map for Fenbendazole, Mebendazole and Ivermectin: A Comparative Mechanistic Analysis for Precision Oncology (2026)
Comparative evidence review • Experimental oncology • Biomarker hypothesis generation
Abstract
Background: Antiparasitic drugs have attracted interest as potential repurposed anticancer compounds because several demonstrate cytotoxic, anti-proliferative, metabolic, anti-angiogenic or signaling effects in experimental cancer models. Fenbendazole and mebendazole are benzimidazole anthelmintics with overlapping microtubule-related pharmacology, whereas ivermectin is a macrocyclic lactone with a substantially different molecular profile. A simple “antiparasitic drugs kill cancer cells” framework, however, obscures potentially important genotype and phenotype dependencies.
Objective: To construct a comparative cancer biomarker map for fenbendazole (FBZ), mebendazole (MBZ), and ivermectin (IVM), focusing on TP53, MDM2, MDM4/MDMX, KRAS, EGFR, MYC, BRAF, RB1, CDKN2A, GLUT1, HK2, PAK1, YAP1, Wnt/β-catenin, PI3K/Akt/mTOR and related cellular phenotypes.
Methods: Experimental, translational and clinical literature was reviewed with emphasis on mechanistic studies, biomarker-associated experiments, cell-line models, xenografts, early clinical trials and recent reviews. Four evidence grades were used: A, direct drug-biomarker evidence; B, strong preclinical mechanistic support; C, indirect or exploratory rationale; and D, insufficient drug-specific evidence to regard the biomarker as predictive.
Results: Fenbendazole has the strongest direct evidence for a p53-regulatory phenotype involving reduced MDM2/MDMX and increased p53/p21 in experimental melanoma and breast-cancer models, together with independent evidence for altered glucose uptake and HK2/GLUT-related metabolism. Fenbendazole also demonstrated genotype-associated activity in KRAS-mutant lung-cancer models. Mebendazole has stronger evidence for tubulin disruption, mitotic arrest, apoptosis, Bcl-2 modulation, MAPK14/p38α and related kinase effects, with particularly substantial investigation in glioma and pancreatic cancer models. Ivermectin has a distinct signaling profile involving PAK1, Wnt/β-catenin, YAP1/Hippo and PI3K/Akt/mTOR, with experimental effects on cancer stem-like cells and multiple tumor types. Cross-drug evidence for TP53, KRAS or general “metabolic vulnerability” should not be assumed to be interchangeable.
Conclusions: The three drugs should not be treated as molecular equivalents. Fenbendazole is most interesting as a multi-node stressor involving p53 regulation, microtubules and metabolism; mebendazole as a tubulin-centered agent with additional kinase, anti-angiogenic and stromal effects; and ivermectin as a signaling-network modulator with particularly strong experimental interest in PAK1, Wnt, YAP and PI3K/Akt/mTOR pathways. None has a prospectively validated cancer biomarker or established anticancer indication. Biomarker-stratified studies using molecularly characterized organoids, xenografts and clinical trials are required before these hypotheses can support treatment selection.
Keywords: fenbendazole; mebendazole; ivermectin; cancer biomarkers; p53; TP53; MDM2; MDMX; KRAS; MYC; HK2; PAK1; YAP1; Wnt; PI3K; AKT; mTOR; microtubules; drug repurposing; precision oncology.
Clinical status: This is a mechanistic and evidence review, not a treatment recommendation. Fenbendazole and mebendazole are benzimidazole antiparasitic agents, while ivermectin is a macrocyclic lactone antiparasitic drug. None is an established standard anticancer treatment. Preclinical activity does not establish human efficacy, and patients should not replace, delay or discontinue evidence-based cancer therapy on the basis of this article.
1. Introduction
Precision oncology is increasingly based on the principle that cancer is not a single disease. Tumors arising in the same anatomical organ can differ dramatically in driver alterations, tumor-suppressor function, metabolism, signaling dependencies, treatment resistance and microenvironment.
This creates a particularly important challenge for drug repurposing. An experimental compound may demonstrate broad cytotoxicity across multiple cancer models while acting through different pathways in different tumor contexts. Conversely, a drug that appears weak in an unselected population may possess greater activity in a molecularly defined subgroup.
Fenbendazole, mebendazole and ivermectin are useful examples of this problem. Fenbendazole and mebendazole share a benzimidazole chemical scaffold and have documented effects on tubulin and cell division, but their activity is not identical. Ivermectin belongs to a different drug class and has been linked experimentally to PAK1, Wnt/β-catenin, Hippo/YAP, PI3K/Akt/mTOR, chloride channels, drug-efflux mechanisms, autophagy and cancer-stem-cell biology. Review: ivermectin multitarget pharmacology.
The central question for this analysis is therefore not simply:
“Which antiparasitic drug is best for cancer?”
Instead, a more useful precision-oncology question is:
“Which molecular and metabolic tumor phenotypes might theoretically create sensitivity to each compound, and how strong is the evidence for each drug-biomarker relationship?”
2. Conceptual Framework
The three compounds can be viewed as occupying different regions of an experimental oncology network.
The mechanistic literature supports these broad distinctions, although individual studies may use concentrations or experimental conditions that do not translate directly to human treatment. Fenbendazole; mebendazole; ivermectin.
3. Evidence-Grading System
| Grade | Definition | Interpretation |
|---|---|---|
| A | Direct evidence that the specific drug was experimentally tested in a defined biomarker/genotype context and showed a corresponding mechanistic effect. | Strong preclinical signal; not clinical validation. |
| B | Strong drug-specific mechanistic evidence but incomplete predictive-biomarker validation. | Promising research hypothesis. |
| C | Indirect evidence, pathway overlap, related-drug evidence or limited experimental support. | Exploratory hypothesis. |
| D | No convincing drug-specific evidence to establish the biomarker as predictive. | Should not be presented as a validated biomarker. |
Important: Grade A does not mean that a drug is clinically effective. It means that the experimental drug-biomarker relationship is comparatively well supported.
4. Comparative Master Cancer Biomarker Map
| Biomarker / phenotype | Fenbendazole | Mebendazole | Ivermectin | Comparative interpretation |
|---|---|---|---|---|
| TP53 wild-type | A | B/C | C | Strongest direct p53 hypothesis for FBZ |
| TP53 mutant | C | C | C | Do not equate mutation with sensitivity; non-p53 mechanisms may remain |
| TP53 null/deleted | D for p53 branch | C for non-p53 mechanisms | C | Shift attention toward p53-independent pathways |
| MDM2 high/amplified + TP53-WT | A/B | C | D/C | FBZ-specific hypothesis |
| MDM4/MDMX high + TP53-WT | A | C | D/C | Strongest direct FBZ regulatory-axis signal |
| KRAS-mutant | A in lung models | B in pancreatic/tumor models; not a universal predictive biomarker | C | KRAS signal strongest for FBZ in NSCLC; MBZ biology overlaps in KRAS-driven pancreatic models |
| EGFR-mutant | D/C | C | C | No validated drug-specific EGFR biomarker |
| MYC-high | B | C | C/B | MYC-related signaling is intriguing but not clinically predictive |
| BRAF-mutant | D/C | C | C | Insufficient evidence for genotype-directed use |
| RB1 loss | D/C | C | C | Cell-cycle rationale but weak predictive data |
| CDKN2A loss | D/C | C | C | Exploratory cell-cycle biomarker |
| GLUT1 / glucose uptake | B | C | C | Metabolic hypothesis stronger for FBZ |
| HK2-high | A/B | C/B | C | Potential metabolic vulnerability; strongest direct evidence for FBZ |
| PAK1-high | D | D/C | A/B | Distinct ivermectin-centered hypothesis |
| YAP1-high / Hippo dysregulation | D | C | A/B | Strong ivermectin gastric-cancer mechanism |
| Wnt/β-catenin activation | C | B/C | A/B | One of ivermectin's most recurrent signaling hypotheses |
| PI3K/Akt/mTOR activation | C | C/B | A/B | More characteristic of ivermectin literature |
| Microtubule dependence | A | A | B/C | Shared major feature of the benzimidazoles |
| Drug-efflux / MDR phenotype | C | C | B | More prominent in ivermectin literature |
| Cancer stem-like phenotype | C | C | B | Strongest recurring ivermectin theme |
5. The p53–MDM2–MDMX Axis: Fenbendazole's Most Distinctive Biomarker Hypothesis
5.1 TP53 Wild-Type
Fenbendazole: Grade A
The most distinctive fenbendazole biomarker observation is its experimental effect on the p53 regulatory network. In melanoma and breast-cancer models, fenbendazole increased p53 and p21 while decreasing MDM2 and MDMX. The study interpreted these findings as promotion of wild-type p53 stability and transcriptional activity through reduction of negative regulators. PubMed PMID 31181622.
This makes TP53-WT + MDM2/MDMX-high a more interesting phenotype than TP53-WT alone.
5.2 MDM2-High or MDM2-Amplified Tumors
Fenbendazole: Grade A/B
MDM2 is an established negative regulator of p53. MDM2 amplification or overexpression can suppress otherwise functional wild-type p53. This is why MDM2 is a major target in precision-oncology drug development. MDM2/MDMX therapeutic review.
The key distinction is that fenbendazole should not be called an MDM2 inhibitor. The published fenbendazole study demonstrated reduced MDM2 protein levels in experimental models; it did not establish fenbendazole as a selective clinical MDM2 inhibitor.
5.3 MDM4/MDMX-High Tumors
Fenbendazole: Grade A
MDMX, also called MDM4, is another major suppressor of p53 transcriptional activity. The fenbendazole p53 study specifically involved tumor models with elevated MDM2/MDMX signaling and observed reductions in both proteins following treatment. PubMed PMID 31181622.
This makes the following phenotype particularly suitable for future research:
TP53 wild-type + MDMX-high ± MDM2-high
The hypothesis remains preclinical and has not been validated as a patient-selection strategy.
6. Mebendazole: Similar Chemical Family, Different Biomarker Landscape
Mebendazole and fenbendazole are both benzimidazole anthelmintics, but it is inappropriate to assume that all biological effects of one automatically apply to the other.
6.1 Microtubules and Mitotic Arrest
Mebendazole: Grade A
Mebendazole has long-standing experimental evidence for tubulin disruption. In lung-cancer models, mebendazole caused abnormal spindle formation, mitotic arrest, caspase activation and cytochrome-c release, supporting a mechanism based strongly on mitotic disruption followed by apoptosis. PubMed PMID 12479701.
This is an important distinction from the p53-centered fenbendazole hypothesis:
6.2 Bcl-2 and Chemoresistant Melanoma
Mebendazole: Grade A/B
In chemoresistant melanoma models, mebendazole induced apoptosis through Bcl-2 phosphorylation, disrupting the interaction between Bcl-2 and pro-apoptotic Bax. This provides a mechanistic phenotype distinct from the MDM2/MDMX-p53 emphasis of fenbendazole. PubMed PMID 18667591.
6.3 MAPK14/p38α
Mebendazole: Grade B
Target-prediction and validation work identified several possible kinase targets for mebendazole, including ABL1, MAPK1/ERK2 and MAPK14/p38α. MAPK14/p38α was particularly potent in the reported biochemical assays. PubMed PMID 33021050.
This creates a broader mebendazole model:
7. KRAS: Where the Comparison Becomes Particularly Interesting
7.1 Fenbendazole and KRAS-Mutant NSCLC
Fenbendazole: Grade A
A 1,271-compound drug-library screen identified benzimidazole derivatives including fenbendazole as compounds with differential activity in KRAS-mutant lung-cancer models. The investigators reported suppression of RAS-related signaling in KRAS-mutated cells. PubMed PMID 30862488.
This makes KRAS-mutant NSCLC one of the most important genotype-specific fenbendazole hypotheses.
7.2 Mebendazole and KRAS-Driven Pancreatic Cancer
Mebendazole: Grade B
Mebendazole has been evaluated in KRAS-driven mouse models of pancreatic cancer, including KC and KPC models. Experimental treatment reduced pancreatic dysplasia and neoplastic burden and affected the stromal/desmoplastic environment. PubMed PMID 34262644.
This does not mean that mebendazole is a direct KRAS inhibitor. Instead, KRAS-driven pancreatic cancer provides a biologically important disease context in which mebendazole's multi-pathway effects can be studied.
7.3 Ivermectin and KRAS
Ivermectin: Grade C
The ivermectin literature is less compelling for a direct KRAS-defined response phenotype. Ivermectin should therefore not be presented as a KRAS-targeted antiparasitic drug.
8. EGFR
Comparative evidence grade: D/C for all three drugs
EGFR mutations are established therapeutic biomarkers in several cancers, especially NSCLC. However, the presence of an EGFR mutation does not establish sensitivity to fenbendazole, mebendazole or ivermectin.
For the current evidence map:
EGFR status should be recorded as an exploratory biomarker, not a validated predictive biomarker for any of the three compounds.
This distinction is especially important when discussing patients already receiving EGFR-targeted therapy. Experimental pathway interactions should not be interpreted as evidence that any antiparasitic compound can replace an approved EGFR inhibitor.
9. MYC
9.1 Fenbendazole
Grade B
Fenbendazole has been associated with MYC-related changes in experimental leukemia work, including transcriptomic/network analysis and experimental reduction of MYC expression. This provides a plausible MYC-centered hypothesis but not a validated MYC biomarker. Scientific Reports.
9.2 Mebendazole
Grade C
Mebendazole can alter proliferation and signaling networks relevant to MYC-driven tumors, but current evidence is insufficient to use MYC amplification as a mebendazole-selection biomarker.
9.3 Ivermectin
Grade C/B
Ivermectin affects multiple proliferation and stemness-related pathways, which can intersect with MYC biology. However, direct MYC amplification or expression as a predictive ivermectin biomarker has not been established.
10. BRAF, RB1 and CDKN2A: The Cell-Cycle/MAPK Layer
10.1 BRAF
Evidence grade: D/C for all three
BRAF is an important oncogenic driver, particularly in melanoma. Yet pathway overlap does not establish that BRAF mutation predicts response to an antiparasitic compound.
For melanoma, the direct fenbendazole p53/MDM2/MDMX evidence is substantially stronger than the evidence for BRAF-selected fenbendazole sensitivity.
10.2 RB1
Evidence grade: D/C
RB1 loss causes major disruption of cell-cycle control. Because both fenbendazole and mebendazole can interfere with mitosis, RB1 status may be useful in exploratory studies. However, no adequate evidence currently establishes RB1 loss as a predictive biomarker for either drug.
10.3 CDKN2A
Evidence grade: D/C
CDKN2A loss may increase cell-cycle dependence and proliferative signaling, especially in melanoma, pancreatic cancer and subsets of NSCLC. It is therefore worth recording in a precision-oncology database but should remain an exploratory variable.
11. GLUT1 and HK2: The Metabolic Layer
11.1 Fenbendazole
GLUT-related phenotype: Grade B
HK2-related phenotype: Grade A/B
Fenbendazole has been reported to reduce glucose uptake, alter GLUT transporter expression and decrease hexokinase II in NSCLC models. The same study also reported mitochondrial p53 translocation and effects on microtubules. PubMed PMID 30093705.
More recent breast-cancer research has linked fenbendazole with HK2 suppression, inhibition of glycolysis and downstream caspase-3/GSDME-associated cell death. PubMed PMID 40756987.
11.2 Mebendazole
Grade C/B
Mebendazole certainly alters cancer-cell metabolism in some experimental systems, but the strongest biomarker identity of mebendazole remains its tubulin and mitotic biology rather than a validated HK2-selected phenotype.
11.3 Ivermectin
Grade C
Ivermectin affects metabolic signaling indirectly through pathways such as PI3K/Akt/mTOR and may affect mitochondrial function and oxidative stress. However, HK2 or GLUT1 expression has not been established as a primary predictive ivermectin biomarker.
12. Ivermectin: A Different Biomarker Architecture
Ivermectin should not simply be placed next to fenbendazole and mebendazole as another tubulin-disrupting benzimidazole. It belongs to a different pharmacological class and has a different experimental signaling landscape.
12.1 PAK1
Grade A/B
PAK1 is one of the most distinctive ivermectin-associated targets in the cancer literature. Experimental studies have reported inhibition of PAK1-associated signaling, suppression of breast-cancer stem-cell formation and links with JAK2/STAT3 signaling. PubMed PMID 31658701.
12.2 YAP1 / Hippo
Grade A/B
In gastric-cancer models, ivermectin was investigated as a YAP1 inhibitor. YAP1 knockdown experiments supported a relationship between YAP1 expression and ivermectin sensitivity, while animal models demonstrated antitumor activity. PubMed PMID 29296196.
This suggests an especially interesting phenotype:
YAP1-high / Hippo-dysregulated gastric cancer → ivermectin research hypothesis
12.3 Wnt/β-Catenin
Grade A/B
Reviews of the ivermectin literature describe inhibition of Wnt-TCF signaling and reductions in Wnt-associated genes including AXIN2, LGR5 and ASCL2, alongside induction of inhibitory regulators. Wnt signaling is particularly relevant to tumor stemness, proliferation and treatment resistance. PubMed PMID 29511601.
12.4 PI3K/Akt/mTOR
Grade A/B
Ivermectin has repeatedly been linked to modulation of the Akt/mTOR pathway and downstream cell survival, autophagy and apoptosis. PubMed PMID 32021111.
13. Comparative Cancer-Type Map
| Cancer type | Fenbendazole | Mebendazole | Ivermectin | Most interesting biomarker hypotheses |
|---|---|---|---|---|
| Melanoma | Strong p53/MDM2/MDMX rationale | Strong tubulin/Bcl-2 evidence | Wnt/stemness signaling | TP53-WT, MDM2/MDMX, Bcl-2, Wnt |
| Breast cancer | p53 + HK2/metabolism | Tubulin + apoptosis | PAK1/STAT3 + CSC | TP53-WT, MDMX, HK2, PAK1 |
| NSCLC | KRAS + p53 + metabolic pathways | Tubulin/mitotic pathway | Wnt/Akt-mTOR and other signaling | KRAS, TP53, HK2, glycolysis |
| Pancreatic cancer | Limited biomarker-specific data | KRAS-driven KPC/KC models + stroma | Wnt/Akt-mTOR | KRAS, TP53, CDKN2A, desmoplasia |
| Glioblastoma / brain tumors | Experimental; limited biomarker specificity | Major research area; tubulin + kinase mechanisms | Experimental | Mitotic signaling, MAPK14, BBB/PK considerations |
| Gastric cancer | Limited | Experimental | YAP1/Hippo | YAP1, Hippo pathway |
| Ovarian cancer | Experimental multi-pathway evidence | Experimental | PI3K/Akt/mTOR, Wnt | Metabolism, Wnt, Akt/mTOR |
| Colorectal cancer | Experimental | Strong preclinical repositioning history | Wnt/β-catenin | Wnt, KRAS, BRAF, metabolic phenotype |
| Leukemia | MYC/network signaling | Experimental apoptosis/cell-cycle effects | Autophagy, PAK1 and survival signaling | MYC, survival signaling, stemness |
14. Brain Tumors: Mebendazole Has the Strongest Translational Record
Mebendazole has progressed farther clinically in oncology than the other two drugs in several contexts, particularly brain tumors.
A phase I study combining mebendazole with temozolomide enrolled patients with high-grade gliomas and evaluated doses up to 200 mg/kg/day. Elevated liver enzymes occurred in several patients at the highest dose, illustrating that even an old antiparasitic drug can have clinically important toxicity at experimental oncology doses. The study concluded that efficacy required further investigation. PubMed PMID 33506200.
A 2026 systematic review of mebendazole in brain tumors concluded that preclinical evidence is broad but that clinical efficacy remains modest, inconsistent and inconclusive, emphasizing the need for better formulation, pharmacokinetic and biomarker studies. 2026 systematic review.
This makes mebendazole an important example of why:
strong preclinical biology + early human safety experience ≠ proven anticancer efficacy.
15. Ivermectin: Preclinical Breadth but Clinical Translation Remains Limited
Ivermectin has generated a particularly broad preclinical literature. Reviews describe effects involving PAK1, Wnt/TCF, Hippo/YAP, Akt/mTOR, chloride channels, autophagy, apoptosis, cancer-stem-cell populations and drug-efflux mechanisms. PubMed PMID 32021111.
A 2020 study evaluating 28 malignant cell lines reported that breast and ovarian cancer cells were among the more sensitive models at the experimental concentration studied, supporting further investigation of ivermectin at potentially achievable concentrations. PubMed PMID 32474842.
Nevertheless, a 2025 review emphasized the translational gap: despite extensive in-vitro and animal evidence, clinical evidence remains limited and large randomized trials confirming an anticancer benefit are lacking. PubMed PMID 40715995.
16. Comparative Mechanistic Scorecard
| Mechanistic domain | Fenbendazole | Mebendazole | Ivermectin |
|---|---|---|---|
| Wild-type p53 activation | High | Moderate / uncertain | Low / indirect |
| MDM2/MDMX relevance | High | Low | Low |
| Microtubule disruption | High | High | Moderate / indirect |
| KRAS-mutant signal | High in NSCLC models | Moderate in selected disease models | Low |
| Metabolic / HK2 signal | High | Moderate / emerging | Low / indirect |
| PAK1 | Low | Low | High |
| YAP1 / Hippo | Low | Low / emerging | High |
| Wnt/β-catenin | Low / indirect | Moderate | High |
| PI3K/Akt/mTOR | Moderate / indirect | Moderate | High |
| Autophagy | Moderate | Moderate | High |
| Cancer stem-cell biology | Exploratory | Exploratory | High experimental interest |
| Clinical oncology experience | Very limited | Greatest of the three | Limited |
17. Proposed Comparative Precision-Oncology Model
The three drugs can be positioned within a broader cancer-biology framework.
18. Highest-Priority Composite Biomarker Phenotypes
18.1 Fenbendazole Phenotype A: p53 Suppression
TP53-WT + MDM2-high and/or MDMX-high
Priority: High
This is the clearest molecular phenotype for testing whether fenbendazole can exploit a functionally suppressed but genetically intact p53 pathway.
18.2 Fenbendazole Phenotype B: KRAS–Metabolic Vulnerability
KRAS-mutant + HK2-high + glycolytic dependence
Priority: High
This combines the KRAS-mutant lung-cancer signal with experimental glucose/HK2 effects and represents a particularly attractive translational hypothesis.
18.3 Fenbendazole Phenotype C: TP53-Loss + KRAS + HK2
TP53-loss + KRAS-mutant + HK2-high
Priority: High experimental interest
This phenotype deliberately shifts away from p53 reactivation and toward metabolic and stress pathways.
18.4 Mebendazole Phenotype A: Mitotic Vulnerability
High proliferative burden + tubulin dependence + apoptosis competence
Priority: High
This phenotype is more consistent with mebendazole's historical experimental pharmacology than assigning it a single mutation.
18.5 Mebendazole Phenotype B: KRAS-Driven Pancreatic Cancer + Desmoplasia
KRAS-driven pancreatic cancer + stromal/desmoplastic phenotype
Priority: Moderate-to-high experimental interest
The pancreatic models are notable because they examine both tumor cells and tumor stroma rather than relying solely on direct cytotoxicity. PubMed PMID 34262644.
18.6 Ivermectin Phenotype A: PAK1/STAT3 Stemness
PAK1-high + STAT3-active + cancer-stem-cell phenotype
Priority: High experimental interest
Breast-cancer stem-cell studies provide direct mechanistic support for this research hypothesis. PubMed PMID 31658701.
18.7 Ivermectin Phenotype B: YAP1-High Gastric Cancer
YAP1-high + Hippo pathway dysregulation
Priority: High experimental interest
The gastric-cancer model provides direct mechanistic support for YAP1-associated sensitivity. PubMed PMID 29296196.
19. What the Three Drugs Have in Common
Despite their differences, several common themes recur across the literature.
First, all three appear capable of producing cellular stress. This can include oxidative stress, mitochondrial dysfunction, ER stress, altered proteostasis or apoptosis.
Second, none should be reduced to a single target. The emerging literature increasingly supports polypharmacology and multi-node effects, particularly for repurposed drugs.
Third, tumor context matters. The same molecular alteration can have different implications depending on tissue type, co-mutations, pathway dependence and drug exposure.
Fourth, in-vitro potency is not equivalent to clinical efficacy. Exposure, pharmacokinetics, formulation, tissue penetration, metabolism and toxicity can all prevent laboratory activity from translating into useful human treatment.
20. What Must Not Be Inferred From This Map
The following conclusions are not currently justified:
- “TP53-mutant cancer should respond to fenbendazole.”
- “MDM2 amplification means fenbendazole is an MDM2 inhibitor.”
- “KRAS mutation means any of the three drugs should work.”
- “EGFR mutation creates sensitivity to fenbendazole, mebendazole or ivermectin.”
- “BRAF-mutant melanoma should receive an antiparasitic drug.”
- “HK2-high tumors are clinically proven to respond to fenbendazole.”
- “PAK1-high tumors are proven to respond to ivermectin in patients.”
- “Mebendazole's clinical use in glioma proves it improves survival.”
These statements exceed the available evidence.
21. Human Evidence: The Translational Gap
21.1 Fenbendazole
Human oncology evidence remains limited. A 2024 review concluded that human pharmacokinetic and safety data are insufficient to establish an oncology regimen and called for appropriately designed clinical trials. PubMed PMID 39197912.
Published reports have also described liver injury associated with self-administration, an especially important consideration in cancer patients receiving concurrent drugs that can themselves cause hepatic toxicity.
21.2 Mebendazole
Mebendazole has the most substantial early clinical oncology experience of the three, including phase I studies in high-grade glioma and phase IIa investigation in advanced gastrointestinal cancers.
In a phase IIa gastrointestinal-cancer study, individualized dosing up to 4 g/day was used in an attempt to target a serum concentration. All evaluable patients experienced disease progression at the eight-week tumor assessment, although pharmacokinetic variability was substantial. PubMed PMID 33903692.
This study is valuable precisely because it demonstrates the difference between promising preclinical biology and uncertain clinical efficacy.
21.3 Ivermectin
Ivermectin's anticancer human evidence remains limited. A 2025 review concluded that there are no large randomized controlled trials confirming an oncology benefit and highlighted the risks associated with self-medication. PubMed PMID 40715995.
22. A Caution About Emerging “Real-World” Evidence
Recent literature has begun to report observational experiences involving ivermectin and mebendazole in people with cancer. However, such studies require particularly careful interpretation because patients may simultaneously receive chemotherapy, radiation, surgery, supplements, dietary interventions or other therapies.
A 2026 prospective observational cohort of 197 patients receiving ivermectin and mebendazole reported patient-reported outcomes at six months. Importantly, the publication is currently accompanied by an Expression of Concern, meaning the findings should not be treated as established evidence of efficacy. PubMed PMID 42203321.
Evidence rule: Observational reports and patient-reported outcomes can generate hypotheses, but they cannot establish that an antiparasitic drug caused tumor regression or improved survival in an individual patient, especially when concurrent treatments are present.
23. Proposed Biomarker Testing Strategy
A future precision-oncology study should not simply enroll “cancer patients.” It should characterize the tumor before exposure.
| Biological layer | Variables to measure | Primary drugs of interest |
|---|---|---|
| p53 integrity | TP53 WT, missense, truncating, null | FBZ, MBZ, IVM |
| p53 suppression | MDM2 amplification/expression; MDM4/MDMX expression | FBZ |
| RAS signaling | KRAS mutation and allele | FBZ, MBZ |
| EGFR | Exon 19 deletion, L858R and other alterations | Exploratory |
| MAPK | BRAF, MAPK14/p38α, ERK | MBZ |
| Cell cycle | RB1, CDKN2A, p21, Ki-67 | FBZ, MBZ |
| MYC | Amplification, expression | FBZ exploratory |
| Metabolism | GLUT1, HK2, glucose uptake, lactate production | FBZ |
| PAK1/STAT3 | PAK1, pSTAT3, IL-6 | IVM |
| Hippo/YAP | YAP1 nuclear localization, CTGF | IVM |
| Wnt | β-catenin, AXIN2, LGR5, ASCL2 | IVM |
| mTOR | pAKT, pS6, mTOR activity | IVM |
24. Experimental Validation Model
A rigorous test of these hypotheses would require genetically characterized models rather than anecdotal treatment experiments.
The critical statistical test is not simply whether the drug reduces tumor growth. It is whether biomarker status modifies treatment response.
25. Comparative Priority Ranking for Biomarker Research
| Research hypothesis | Drug | Priority | Reason |
|---|---|---|---|
| TP53-WT + MDM2/MDMX-high | Fenbendazole | Very high | Direct p53-regulatory evidence |
| KRAS-mutant NSCLC | Fenbendazole | Very high | Genotype-specific screening signal |
| HK2-high / glycolytic tumor | Fenbendazole | Very high | Direct metabolic mechanism |
| Tubulin/mitotic vulnerability | Mebendazole | Very high | Strongest historical pharmacologic rationale |
| KRAS-driven pancreatic cancer + desmoplasia | Mebendazole | High | In-vivo tumor + stromal effects |
| MAPK14/p38α dependence | Mebendazole | Moderate-high | Biochemical target validation |
| PAK1-high / STAT3-active cancer | Ivermectin | High | Distinct drug-specific pathway |
| YAP1-high gastric cancer | Ivermectin | High | Drug-specific experimental evidence |
| Wnt/β-catenin-high tumors | Ivermectin | High | Repeated pathway-level evidence |
| PI3K/Akt/mTOR-active tumors | Ivermectin | Moderate-high | Repeated mechanistic association |
26. Why a Three-Drug Biomarker Map Is More Useful Than a Simple Drug Comparison
A conventional drug comparison might conclude that all three compounds demonstrate anticancer activity in laboratory models. That statement is technically true in broad terms but scientifically incomplete.
The more useful distinction is:
| Drug | Primary experimental identity | Most interesting biomarker layer |
|---|---|---|
| Fenbendazole | Multi-pathway stressor with p53, microtubule and metabolic effects | TP53-WT / MDM2-MDMX; KRAS; HK2 |
| Mebendazole | Tubulin-centered antiproliferative agent with kinase, apoptotic, anti-angiogenic and stromal effects | Mitotic vulnerability; MAPK14; KRAS-driven disease contexts |
| Ivermectin | Signaling-network modulator affecting PAK1, YAP, Wnt and Akt/mTOR | PAK1; YAP1; Wnt; PI3K/Akt/mTOR; CSC phenotype |
27. Discussion
The comparative analysis reveals that the three compounds should not be grouped simply because all originated as antiparasitic drugs.
Fenbendazole has a particularly interesting relationship with the p53 regulatory network. The combination of TP53-wild-type status with MDM2/MDMX elevation provides a biologically coherent model in which p53 is genetically intact but functionally suppressed. Fenbendazole-associated reductions in MDM2/MDMX and increases in p53/p21 give this hypothesis an unusually direct experimental basis.
Fenbendazole also has a second potentially important identity as a metabolic stressor. The reported effects on glucose uptake, GLUT-related expression and HK2 suggest a possible vulnerability in highly glycolytic tumors. This becomes especially interesting when combined with KRAS biology in NSCLC.
Mebendazole is different. Its strongest identity remains tubulin and mitotic disruption. Its effects on Bcl-2, MAPK14/p38α, angiogenesis and pancreatic tumor stroma broaden the mechanism but do not yet produce a single validated molecular biomarker.
Ivermectin is different again. Its experimental map is dominated by signaling networks rather than primarily by tubulin. PAK1, YAP1, Wnt/β-catenin and Akt/mTOR emerge as recurring nodes, with additional interest in autophagy, apoptosis, immunogenic cell death and cancer-stem-like cells.
This creates three potentially distinct precision-oncology research philosophies:
These are fundamentally different hypotheses.
28. Translational Implications
A precision-oncology approach could eventually move beyond a drug-centered model toward a tumor-vulnerability-centered model.
For example:
Example 1: TP53-WT + MDM2-high + MDMX-high → investigate fenbendazole-associated p53 pharmacodynamics.
Example 2: KRAS-mutant + HK2-high NSCLC → investigate fenbendazole-associated metabolic and RAS-pathway effects.
Example 3: KRAS-driven pancreatic cancer + severe desmoplasia → investigate mebendazole's combined tumor/stromal effects.
Example 4: PAK1-high + STAT3-active breast tumor → investigate ivermectin-related pathway modulation.
Example 5: YAP1-high gastric cancer → investigate ivermectin/YAP1 dependence.
These examples are research hypotheses. They are not evidence-based prescribing algorithms.
29. Limitations
This analysis has several limitations.
First, much of the literature is based on cell lines and animal models.
Second, experimental concentrations can exceed clinically achievable free-drug exposure.
Third, protein expression is not necessarily equivalent to pathway dependence.
Fourth, tumor heterogeneity can produce different responses among primary and metastatic lesions.
Fifth, the three drugs have distinct pharmacokinetic properties, making direct comparisons based solely on in-vitro potency inappropriate.
Sixth, many pathways discussed here are affected by numerous cancer drugs. Demonstrating that fenbendazole, mebendazole or ivermectin changes a pathway does not prove that the pathway is the dominant therapeutic mechanism.
Seventh, the lack of adequately powered biomarker-stratified randomized trials remains the central translational limitation.
30. Conclusions
Fenbendazole, mebendazole and ivermectin should not be considered interchangeable “anticancer antiparasitic drugs.” Their experimental biomarker landscapes are substantially different.
Fenbendazole has the strongest current experimental case for a biomarker strategy centered on TP53-wild-type tumors with MDM2/MDMX-mediated p53 suppression. Its second major research axis is tumor metabolism involving glucose uptake and HK2, with an additional genotype-specific signal in KRAS-mutant NSCLC.
Mebendazole has the strongest evidence for tubulin-dependent mitotic disruption, with additional mechanisms involving Bcl-2, kinase signaling, angiogenesis and tumor stroma. Its clinical development history, particularly in brain tumors, makes it the most clinically explored of the three, but efficacy remains unproven.
Ivermectin has a distinct signaling-centered profile involving PAK1, YAP1/Hippo, Wnt/β-catenin and PI3K/Akt/mTOR, with substantial experimental interest in cancer stem-like populations and autophagy. Clinical validation remains limited.
The most promising direction is therefore not to ask which of the three drugs is universally “best.” A more scientifically defensible question is whether molecularly defined tumor states can predict differential vulnerability to each compound.
That question can be answered only through controlled laboratory experiments, pharmacokinetic studies, biomarker-guided translational research and ultimately properly designed clinical trials.
31. Proposed Research Database Schema
For a cancer knowledge graph or repurposed-drug evidence database, each record should contain:
| Field | Example |
|---|---|
| Drug | Fenbendazole |
| Cancer type | NSCLC |
| Molecular subtype | KRAS-mutant |
| Biomarker | KRAS G12C |
| Secondary biomarker | HK2-high |
| Pathway | RAS / glycolysis |
| Mechanism | Altered glucose utilization; RAS-related signaling suppression |
| Experimental model | Cell line / organoid / mouse |
| Response | Growth inhibition / apoptosis / metabolic change |
| Evidence grade | A |
| Human evidence | Insufficient |
| Clinical validation | None established |
| Contradictory evidence | Record separately |
| Source | PubMed / DOI / journal |
This architecture would prevent the common problem of collapsing laboratory, animal, observational and clinical evidence into a single “works/doesn't work” conclusion.
32. Final Evidence Statement
At the present evidence level, fenbendazole, mebendazole and ivermectin should be regarded as experimental repurposing candidates rather than validated cancer therapies. The biomarker associations described in this article are intended to identify research priorities, not to provide treatment-selection rules.
33. References
- Mrkvová Z, et al. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. Molecules. 2019;24(11):2152. PubMed.
- Dogra N, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018. PubMed PMID 30093705.
- Dobashi Y, et al. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells. PubMed PMID 22745125.
- Yokoyama Y, et al. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. PubMed PMID 30862488.
- Moll U, et al. The p53/MDM2/MDMX-targeted therapies — a clinical synopsis. PubMed.
- Bai X, et al. Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology. PubMed.
- Mukhopadhyay T, et al. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. PubMed PMID 12479701.
- Doudican NA, et al. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. PubMed PMID 18667591.
- Alam A, et al. In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor. PubMed PMID 33021050.
- Bai RY, et al. Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer. PubMed PMID 34262644.
- Galluzzi L, et al. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. PubMed PMID 33506200.
- Bourgon R, et al. A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. PubMed PMID 33903692.
- Juarez M, et al. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. PubMed PMID 32474842.
- Juarez M, et al. Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin. PubMed PMID 32021111.
- Dou Q, et al. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. PubMed PMID 29511601.
- Dadashpour M, et al. Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. PubMed PMID 29296196.
- Li Z, et al. The PAK1-Stat3 Signaling Pathway Activates IL-6 Gene Transcription and Human Breast Cancer Stem Cell Formation. PubMed PMID 31658701.
- Nguyen T, et al. Oral Fenbendazole for Cancer Therapy in Humans and Animals. 2024. PubMed PMID 39197912.
- Liu J, et al. From anthelmintic to neuro-oncology: A systematic review of mebendazole repurposing for brain tumour therapy. 2026. PubMed PMID 42120351.
- Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? 2025. PubMed PMID 40715995.
- Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. 2026. PubMed PMID 42203321. Note: PubMed currently displays an Expression of Concern for this publication.
34. Medical and Editorial Disclaimer
This article is an educational evidence review and does not constitute medical advice or a recommendation to use fenbendazole, mebendazole or ivermectin for cancer. The drugs discussed have different pharmacological properties and evidence bases. Experimental anticancer activity in cell culture or animals does not establish human efficacy.
Patients with cancer should not delay, discontinue or replace standard treatment with an antiparasitic drug based on laboratory experiments, case reports, observational studies, social-media claims or this article. Experimental use may also involve drug interactions, formulation differences, pharmacokinetic limitations and organ toxicity.
Evidence classification: A/B/C/D grades in this article describe the strength of the drug-specific mechanistic evidence and should not be interpreted as regulatory approval, clinical efficacy rankings or treatment recommendations.
.png)
.png)
Comments
Post a Comment